COMMUNIQUÉS West-GlobeNewswire

BellaSeno’s regenerative scaffolds signal new era for breast surgery
30/06/2026
MedTech company, BellaSeno, is accelerating human trials of its proprietary breast scaffolds as it moves regenerative breast surgery toward clinical adoption LEIPZIG, Germany and SYDNEY, June 30, 2026 (GLOBE NEWSWIRE [...]
Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control
30/06/2026
Both Annamycin dose arms outperformed control on the primary endpoint of complete remission (CR): 43% and 36% versus 12% — reported on a full intent-to-treat (ITT) basis with no patient exclusions Composite complete [...]
Quoin Pharmaceuticals Receives U.S. Notice of Allowance for Patent Covering Combination Treatment for Netherton Syndrome
30/06/2026
Allowed Claims Cover a Method of Treating Netherton Syndrome with a Topical Serine Protease Inhibitor and an Anti-Inflammatory Agent, Including in Patients with SPINK5 Mutations ASHBURN, Va., June 30, 2026 (GLOBE [...]
Les échafaudages régénératifs de BellaSeno annoncent l’avènement d’une nouvelle ère pour la chirurgie mammaire
30/06/2026
L’entreprise de technologies médicales BellaSeno intensifie son programme d’essais cliniques dans le domaine des échafaudages mammaires exclusifs, tandis que la chirurgie mammaire régénérative progresse vers une [...]
Vivos’ Vida® Appliance Shows Statistically Significant Improvement in Insomnia Severity in 100% of Study Participants
30/06/2026
LITTLETON, Colo., June 30, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS) , a leading medical device and healthcare services company focused on the treatment of breathing‑ [...]
Jushi Celebrates Enactment of Virginia Adult-Use Cannabis Legislation
30/06/2026
BOCA RATON, Fla., June 30, 2026 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (CSE: JUSH ) (OTCQX: JUSHF ) ("Jushi" or the "Company"), a vertically integrated, multi-state cannabis operator, celebrates the enactment of [...]
Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
30/06/2026
Phase 3 clinical trial will evaluate aglatimagene besadenovec plus valacyclovir in combination with continued pembrolizumab versus standard-of-care docetaxel chemotherapy in patients with metastatic, non-squamous, non- [...]
ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel
30/06/2026
Strengthens Leadership with Veteran Executives with Decades of Industry Experience Scott Garland Succeeds Co-Founder Corey Goodman, Ph.D., After More Than a Decade of Foundational Leadership SOUTH SAN FRANCISCO, Calif [...]
Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic
30/06/2026
Key U.S. patent now protects exclusivity for developing stenoparib with the stenoparib-DRP ® until April 2042 TARPON SPRINGS, Fla., June 30, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR [...]
FocalTherics™ Announces Successful Launch of First Commercial Endometriosis Focal One® Program in Europe with Treatment of Initial Patients
30/06/2026
FocalTherics™ Announces Successful Launch of First Commercial Endometriosis Focal One® Program in Europe with Treatment of Initial Patients AUSTIN, Texas, June 30, 2026 (GLOBE NEWSWIRE) -- FocalTherics™ (Nasdaq: FOCL) ( [...]
LB Pharmaceuticals Appoints Christopher Zergebel as Senior Vice President, Clinical Operations
30/06/2026
NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar [...]
Vamorolone Demonstrates On-Target Glucocorticoid Activity Without the Immunosuppression Characteristic of Traditional Corticosteroids at Clinical Doses
30/06/2026
Data Demonstrate Vamorolone’s Balanced Corticosteroid Profile with On-Target Glucocorticoid Activity and Without Evidence of Significant Immunosuppressive Activity at Clinical Doses CORAL GABLES, Fla., June 30, 2026 ( [...]
TerrAscend Signs Agreement to Acquire Fifth Dispensary in New Jersey
30/06/2026
Aunt Mary’s, a high-performing dispensary in Hunterdon County, generates over $10 million in annualized revenue Transaction expected to be immediately accretive on an EBITDA and free cash flow basis, further extending [...]
Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board
30/06/2026
SOUTH SAN FRANCISCO, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for [...]
Imviva Biotech Receives FDA IDE Authorization for clonoSEQ® Assay in TENACITY-01 Clinical Trial
30/06/2026
Highly sensitive next-generation sequencing-based MRD testing will identify eligible patients with T-cell malignancies for trial enrollment and precisely evaluate treatment response BOSTON, June 30, 2026 (GLOBE NEWSWIRE [...]
Plus Therapeutics Provides Mid-Year Business Update Including Corporate Rebranding
30/06/2026
Plus Therapeutics to become Cerenome, to trade under new Nasdaq ticker CNSY on August 3, 2026 Affirms 2026 guidance on key milestones Reports positive CNSide ® commercial progress HOUSTON, June 30, 2026 (GLOBE NEWSWIRE [...]
Biodexa Announces Pricing of $3.5 Million Registered Direct Offering & Concurrent Private Placement of Pre-Funded Warrants and Warrants
30/06/2026
June 30, 2026 Biodexa Announces Pricing of $3.5 Million Registered Direct Offering & Concurrent Private Placement of Pre-Funded Warrants and Warrants Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX) (“Biodexa” or the “ [...]
FEATOL Rolls Out Reinforced Lower Back Brace to Help Adults During Work, Driving, and in Chronic Pain
30/06/2026
The latest adjustable lumbar support from FEATOL combines stability with comfort, providing much-needed mobility support for those experiencing lower back fatigue NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- With more [...]
Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)
30/06/2026
Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated safety profile for [...]

Pages